2024

Spear, S. et al. (2024) PTEN loss shapes macrophage dynamics in high grade serous ovarian carcinoma. Cancer Research, (doi: 10.1158/0008-5472.can-23-3890) (PMID:39186679) (PMCID:PMC7616669) (In Press)

Manchanda, R. et al. (2024) Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer. Journal of the National Comprehensive Cancer Network, 22(2D), e237331. (doi: 10.6004/jnccn.2023.7331) (PMID:38866043)

Spiliopoulou, P. et al. (2024) A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301). Journal of Experimental and Clinical Cancer Research, 43(1), 100. (doi: 10.1186/s13046-024-03010-1) (PMID:38566164) (PMCID:PMC10986017)

Lee, C. L. et al. (2024) Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential biomarker for isocitrate dehydrogenase (IDH1/2) mutant cholangiocarcinoma. Molecular Cancer Therapeutics, 23(3), pp. 394-399. (doi: 10.1158/1535-7163.mct-23-0460) (PMID:38015561) (PMCID:PMC10911702)

Spiliopoulou, P. , Kaur, P., Hammett, T., Di Conza, G. and Lahn, M. (2024) Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers. Cancer Drug Resistance, 7, 2. (doi: 10.20517/cdr.2023.46) (PMID:38318526) (PMCID:PMC10838381)

Spiliopoulou, P. , Lopes, C. D. H. and Spreafico, A. (2024) Promising and minimally invasive biomarkers: targeting melanoma. Cells, 13(1), 19. (doi: 10.3390/cells13010019) (PMID:38201222) (PMCID:PMC10777980)

2023

Janse van Rensburg, H. J., Spiliopoulou, P. , Makhzoum, A. and Healy, B. D. (2023) Remitting seronegative symmetrical synovitis with pitting edema: a case report of an immune-related adverse event following surgery. Case Reports in Oncology, 16(1), pp. 662-669. (doi: 10.1159/000532004) (PMID:37933314) (PMCID:PMC10625819)

Genta, S. et al. (2023) Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT). Journal of Experimental and Clinical Cancer Research, 42(1), 276. (doi: 10.1186/s13046-023-02851-6) (PMID:37865776) (PMCID:PMC10589949)

Mittal, A. et al. (2023) The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma. British Journal of Cancer, 128(10), pp. 1888-1896. (doi: 10.1038/s41416-023-02166-5) (PMID:36859686) (PMCID:PMC10147707)

Spiliopoulou, P. et al. (2023) Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy. Cell Death and Disease, 14(1), 49. (doi: 10.1038/s41419-022-05548-4) (PMID:36670100) (PMCID:PMC9853486)

Spiliopoulou, P. , Vornicova, O., Genta, S. and Spreafico, A. (2023) Shaping the future of immunotherapy targets and biomarkers in melanoma and non-melanoma cutaneous cancers. International Journal of Molecular Sciences, 24(2), 1294. (doi: 10.3390/ijms24021294) (PMID:36674809) (PMCID:PMC9862040)

2022

Janse van Rensburg, H. J., Spiliopoulou, P. and Siu, L. L. (2022) Circulating biomarkers for therapeutic monitoring of anti-cancer agents. Oncologist, 27(5), pp. 352-362. (doi: 10.1093/oncolo/oyac047) (PMID:35285488) (PMCID:PMC9074993)

Spiliopoulou, P. , Yang, S.Y. C., Bruce, J. P., Wang, B. X., Berman, H. K., Pugh, T. J. and Siu, L. L. (2022) All is not lost: learning from 9p21 loss in cancer. Trends in Immunology, 43(5), pp. 379-390. (doi: 10.1016/j.it.2022.03.003) (PMID:35379580)

Spiliopoulou, P. et al. (2022) Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma. Molecular Cancer Therapeutics, 21(4), pp. 522-534. (doi: 10.1158/1535-7163.MCT-21-0743) (PMID:35131874) (PMCID:PMC9377747)

2021

Spiliopoulou, P. , Hinsley, S. , Mcneish, I. A. , Roxburgh, P. and Glasspool, R. (2021) Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 31, pp. 1037-1044. (doi: 10.1136/ijgc-2021-002467) (PMID:34016703)

2020

Leung, E. Y.L. et al. (2020) NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer. Molecular Therapy - Oncolytics, 16, pp. 289-301. (doi: 10.1016/j.omto.2020.02.001) (PMID:32195317) (PMCID:PMC7068056)

2019

MacPherson, I. R. et al. (2019) A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research, 22, 1. (doi: 10.1186/s13058-019-1178-0) (PMID:31892325) (PMCID:PMC6938617)

2018

Fleming, K., McGuinness, J., Kipgen, D., Glen, H. and Spiliopoulou, P. (2018) A case of Lenvatinib-induced Focal Segmental Glomerulosclerosis (FSGS) in metastatic medullary thyroid cancer. Case Reports in Oncological Medicine, 2018, 6927639. (doi: 10.1155/2018/6927639) (PMID:30402314) (PMCID:PMC6192131)

Rust, K. et al. (2018) Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience. BJOG: An International Journal of Obstetrics and Gynaecology, 125(11), pp. 1451-1458. (doi: 10.1111/1471-0528.15171) (PMID:29460478)

2017

Graham, J., Spiliopoulou, P. , Arbuckle, R., Bridge, J. A. and Cassidy, J. (2017) A pilot study of subjective well-being in colorectal cancer patients and their caregivers. Patient Related Outcome Measures, 8, pp. 111-119. (doi: 10.2147/PROM.S141815) (PMID:29089790) (PMCID:PMC5656346)

2016

Sharma, P. et al. (2016) Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncology, 17(11), pp. 1590-1598. (doi: 10.1016/S1470-2045(16)30496-X) (PMID:27733243) (PMCID:PMC5648054)

Bilsland, A. E. , Spiliopoulou, P. and Evans, T.R. J. (2016) Virotherapy: cancer gene therapy at last? F1000Research, 5, 2105. (doi: 10.12688/f1000research.8211.1) (PMID:27635234) (PMCID:PMC5007754)

Spiliopoulou, P. , Bowers, S. P., Gibson, S., White, J. and Reed, N. (2016) Three cases of thyroid cancer following the diagnosis of testicular cancer: treatment-related complication or genetics? Scottish Medical Journal, 61(2), pp. 111-116. (doi: 10.1177/0036933016635409) (PMID:27069005)

2015

Lemech, C., Dua, D., Newmark, J., Saggese, M., Simmons, E., Spiliopoulou, P. and Arkenau, H.-T. (2015) Patients' perceptions of research biopsies in Phase I Oncology Trials. Oncology, 88(2), pp. 95-102. (doi: 10.1159/000368161) (PMID:25322682)

Lindsay, C. R., Spiliopoulou, P. and Waterston, A. (2015) Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Therapeutic Advances in Medical Oncology, 7(2), pp. 107-121. (doi: 10.1177/1758834014566619) (PMID:25755683) (PMCID:PMC4346213)

2014

Spiliopoulou, P. and Arkenau, H.-T. (2014) Rationally designed treatment for metastatic colorectal cancer: Current drug development strategies. World Journal of Gastroenterology, 20(30), pp. 10288-10295. (doi: 10.3748/wjg.v20.i30.10288) (PMID:25132745) (PMCID:PMC4130836)

2011

Spiliopoulou, P. , Panwar, U. and Davidson, N. (2011) Rectal small cell carcinoma: A case report and review of the literature. Case Reports in Oncology, 4(3), pp. 475-480. (doi: 10.1159/000332760) (PMID:22114573) (PMCID:PMC3220900)

Articles

Spear, S. et al. (2024) PTEN loss shapes macrophage dynamics in high grade serous ovarian carcinoma. Cancer Research, (doi: 10.1158/0008-5472.can-23-3890) (PMID:39186679) (PMCID:PMC7616669) (In Press)

Manchanda, R. et al. (2024) Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer. Journal of the National Comprehensive Cancer Network, 22(2D), e237331. (doi: 10.6004/jnccn.2023.7331) (PMID:38866043)

Spiliopoulou, P. et al. (2024) A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301). Journal of Experimental and Clinical Cancer Research, 43(1), 100. (doi: 10.1186/s13046-024-03010-1) (PMID:38566164) (PMCID:PMC10986017)

Lee, C. L. et al. (2024) Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential biomarker for isocitrate dehydrogenase (IDH1/2) mutant cholangiocarcinoma. Molecular Cancer Therapeutics, 23(3), pp. 394-399. (doi: 10.1158/1535-7163.mct-23-0460) (PMID:38015561) (PMCID:PMC10911702)

Spiliopoulou, P. , Kaur, P., Hammett, T., Di Conza, G. and Lahn, M. (2024) Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers. Cancer Drug Resistance, 7, 2. (doi: 10.20517/cdr.2023.46) (PMID:38318526) (PMCID:PMC10838381)

Spiliopoulou, P. , Lopes, C. D. H. and Spreafico, A. (2024) Promising and minimally invasive biomarkers: targeting melanoma. Cells, 13(1), 19. (doi: 10.3390/cells13010019) (PMID:38201222) (PMCID:PMC10777980)

Janse van Rensburg, H. J., Spiliopoulou, P. , Makhzoum, A. and Healy, B. D. (2023) Remitting seronegative symmetrical synovitis with pitting edema: a case report of an immune-related adverse event following surgery. Case Reports in Oncology, 16(1), pp. 662-669. (doi: 10.1159/000532004) (PMID:37933314) (PMCID:PMC10625819)

Genta, S. et al. (2023) Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT). Journal of Experimental and Clinical Cancer Research, 42(1), 276. (doi: 10.1186/s13046-023-02851-6) (PMID:37865776) (PMCID:PMC10589949)

Mittal, A. et al. (2023) The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma. British Journal of Cancer, 128(10), pp. 1888-1896. (doi: 10.1038/s41416-023-02166-5) (PMID:36859686) (PMCID:PMC10147707)

Spiliopoulou, P. et al. (2023) Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy. Cell Death and Disease, 14(1), 49. (doi: 10.1038/s41419-022-05548-4) (PMID:36670100) (PMCID:PMC9853486)

Spiliopoulou, P. , Vornicova, O., Genta, S. and Spreafico, A. (2023) Shaping the future of immunotherapy targets and biomarkers in melanoma and non-melanoma cutaneous cancers. International Journal of Molecular Sciences, 24(2), 1294. (doi: 10.3390/ijms24021294) (PMID:36674809) (PMCID:PMC9862040)

Janse van Rensburg, H. J., Spiliopoulou, P. and Siu, L. L. (2022) Circulating biomarkers for therapeutic monitoring of anti-cancer agents. Oncologist, 27(5), pp. 352-362. (doi: 10.1093/oncolo/oyac047) (PMID:35285488) (PMCID:PMC9074993)

Spiliopoulou, P. , Yang, S.Y. C., Bruce, J. P., Wang, B. X., Berman, H. K., Pugh, T. J. and Siu, L. L. (2022) All is not lost: learning from 9p21 loss in cancer. Trends in Immunology, 43(5), pp. 379-390. (doi: 10.1016/j.it.2022.03.003) (PMID:35379580)

Spiliopoulou, P. et al. (2022) Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma. Molecular Cancer Therapeutics, 21(4), pp. 522-534. (doi: 10.1158/1535-7163.MCT-21-0743) (PMID:35131874) (PMCID:PMC9377747)

Spiliopoulou, P. , Hinsley, S. , Mcneish, I. A. , Roxburgh, P. and Glasspool, R. (2021) Metronomic oral cyclophosphamide in relapsed ovarian cancer. International Journal of Gynecological Cancer, 31, pp. 1037-1044. (doi: 10.1136/ijgc-2021-002467) (PMID:34016703)

Leung, E. Y.L. et al. (2020) NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer. Molecular Therapy - Oncolytics, 16, pp. 289-301. (doi: 10.1016/j.omto.2020.02.001) (PMID:32195317) (PMCID:PMC7068056)

MacPherson, I. R. et al. (2019) A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research, 22, 1. (doi: 10.1186/s13058-019-1178-0) (PMID:31892325) (PMCID:PMC6938617)

Fleming, K., McGuinness, J., Kipgen, D., Glen, H. and Spiliopoulou, P. (2018) A case of Lenvatinib-induced Focal Segmental Glomerulosclerosis (FSGS) in metastatic medullary thyroid cancer. Case Reports in Oncological Medicine, 2018, 6927639. (doi: 10.1155/2018/6927639) (PMID:30402314) (PMCID:PMC6192131)

Rust, K. et al. (2018) Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience. BJOG: An International Journal of Obstetrics and Gynaecology, 125(11), pp. 1451-1458. (doi: 10.1111/1471-0528.15171) (PMID:29460478)

Graham, J., Spiliopoulou, P. , Arbuckle, R., Bridge, J. A. and Cassidy, J. (2017) A pilot study of subjective well-being in colorectal cancer patients and their caregivers. Patient Related Outcome Measures, 8, pp. 111-119. (doi: 10.2147/PROM.S141815) (PMID:29089790) (PMCID:PMC5656346)

Sharma, P. et al. (2016) Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncology, 17(11), pp. 1590-1598. (doi: 10.1016/S1470-2045(16)30496-X) (PMID:27733243) (PMCID:PMC5648054)

Bilsland, A. E. , Spiliopoulou, P. and Evans, T.R. J. (2016) Virotherapy: cancer gene therapy at last? F1000Research, 5, 2105. (doi: 10.12688/f1000research.8211.1) (PMID:27635234) (PMCID:PMC5007754)

Spiliopoulou, P. , Bowers, S. P., Gibson, S., White, J. and Reed, N. (2016) Three cases of thyroid cancer following the diagnosis of testicular cancer: treatment-related complication or genetics? Scottish Medical Journal, 61(2), pp. 111-116. (doi: 10.1177/0036933016635409) (PMID:27069005)

Lemech, C., Dua, D., Newmark, J., Saggese, M., Simmons, E., Spiliopoulou, P. and Arkenau, H.-T. (2015) Patients' perceptions of research biopsies in Phase I Oncology Trials. Oncology, 88(2), pp. 95-102. (doi: 10.1159/000368161) (PMID:25322682)

Lindsay, C. R., Spiliopoulou, P. and Waterston, A. (2015) Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Therapeutic Advances in Medical Oncology, 7(2), pp. 107-121. (doi: 10.1177/1758834014566619) (PMID:25755683) (PMCID:PMC4346213)

Spiliopoulou, P. and Arkenau, H.-T. (2014) Rationally designed treatment for metastatic colorectal cancer: Current drug development strategies. World Journal of Gastroenterology, 20(30), pp. 10288-10295. (doi: 10.3748/wjg.v20.i30.10288) (PMID:25132745) (PMCID:PMC4130836)

Spiliopoulou, P. , Panwar, U. and Davidson, N. (2011) Rectal small cell carcinoma: A case report and review of the literature. Case Reports in Oncology, 4(3), pp. 475-480. (doi: 10.1159/000332760) (PMID:22114573) (PMCID:PMC3220900)